Phenylephrine
MedicationSudafed PE
Decongestant
Research strength: 3 / 5
MotherToBaby says its cited first-trimester evidence did not show an overall increase in birth defects. In a study comparing babies with and without birth defects, Yau et al. found an association with a specific heart defect in four exposed cases; all four had other anomalies, and the authors said chance was possible because the number was small. MotherToBaby says phenylephrine miscarriage studies have not been done, while the FDA injection label reports no miscarriage data after fetal exposure to the IV form. MotherToBaby describes reduced placental blood flow as a theoretical concern and says phenylephrine can raise blood pressure. Ask your provider about your situation.
Last reviewed: 2026-10-16
Research strength: 2 / 5
MotherToBaby says its cited birth-defect evidence focuses on the first trimester. Yau et al. did not observe the first-trimester associations they tested in second- or third-trimester exposure, but those results cover only specific defects. MotherToBaby says effects on preterm delivery or birth weight are unknown, describes reduced placental blood flow as a theoretical concern, and says phenylephrine can raise blood pressure. The FDA injection label says there are no first- or second-trimester use data for the IV form, which does not answer questions about oral OTC use. Ask your provider about your situation.
Last reviewed: 2026-10-16
Research strength: 2 / 5
The FDA injection label summarizes randomized trials and meta-analyses during cesarean care and says they have not established a drug-associated risk of major birth defects or miscarriage; those studies also did not identify adverse maternal outcomes or infant Apgar scores. The label reports no first- or second-trimester use data and says there are no studies during the months when organs form to draw conclusions about birth-defect risk. A 2026 randomized study of 80 term patients compared two IV phenylephrine regimens and found no difference in newborn outcomes or maternal complications. These findings concern IV use during cesarean care, not oral or nasal use during pregnancy. Ask your provider about your situation.
Last reviewed: 2026-10-16
Phenylephrine — Breastfeeding
Research strength: 1 / 5
MotherToBaby says studies have not measured whether phenylephrine enters human milk, and animal studies suggest it may reduce milk supply. LactMed says oral phenylephrine is unlikely to reach an infant because very little is absorbed by mouth, but oral or IV use might reduce milk production; an alternative may be preferred, especially for a newborn or preterm infant. The NHS Specialist Pharmacy Service advises avoiding phenylephrine combination products if possible, especially with a newborn while breastfeeding is being established. LactMed reports no published human milk-level or infant-effect information; these sources describe a possible supply effect but do not report a confirmed infant effect from maternal use. Ask your provider about your situation.
Last reviewed: 2026-10-16
Sources
- MotherToBaby: Phenylephrine Fact SheetTeratology service
- LactMed (NIH): PhenylephrineUS government
- NHS Specialist Pharmacy Service: Using paracetamol during breastfeedingUK government
Pregnancy
MotherToBaby says its cited first-trimester studies did not show an overall increase in birth defects, while it also describes a report of minor eye or ear differences that it says were not birth defects. It states that phenylephrine miscarriage studies have not been done, effects on preterm delivery and low birth weight are unknown, and reduced placental blood flow is a theoretical concern. Yau et al. (2013) read in full: a case-control study of 12,734 infants with malformations and 7,606 non-malformed controls in the United States and Canada. For first-trimester oral phenylephrine, it reported an association with endocardial cushion defect (OR 8.0, 95% CI 2.5 to 25.3) based on four exposed cases; all four had multiple anomalies. The authors said chance was possible because the exposed numbers were small and multiple comparisons were made. Their study did not observe the tested first-trimester associations in second- or third-trimester exposure. The FDA injection label summarizes randomized trials and meta-analyses during cesarean care, but says no first- or second-trimester injection data or organogenesis studies are available. Those IV findings do not establish evidence for oral or nasal use.
Breastfeeding
LactMed, revised 2026-04-15, says oral bioavailability is negligible and infant exposure is unlikely, but oral or IV use might reduce milk production; an alternative may be preferred, especially for a newborn or preterm infant. It reports that relevant published human information was not found for maternal levels, infant levels, infant effects, or human effects on lactation. MotherToBaby also says human milk studies have not been done and cites animal data suggesting lower supply. NHS Specialist Pharmacy Service advises avoiding phenylephrine combination products if possible, especially with a newborn while breastfeeding is being established; it expects small transfer based on drug properties and describes supply suppression as theoretical.
Phenylephrine is a sympathomimetic medicine that acts on alpha-1 receptors. It is sold in oral products for nasal congestion and is also used in nasal sprays, eye products, and IV injection. The OTC oral efficacy action concerns oral use as a nasal decongestant only; the injection label and the EMA eye-drop review concern different routes and settings. Evidence for one route should not be treated as evidence for another.
What was tested
The main pregnancy study read was Yau et al. (2013), a case-control study using 1993-2010 data from 12,734 infants with malformations and 7,606 controls; the phenylephrine signal involved four first-trimester exposed cases. The 2025 FDA injection label summarizes randomized trials and meta-analyses in pregnant patients receiving phenylephrine by IV during cesarean section. The bounded PubMed search for 2025-10-16 through 2026-10-16 returned 26 records. The directly relevant new human pregnancy study included 80 term patients receiving IV phenylephrine during elective cesarean delivery; it compared bolus and infusion regimens, not oral decongestant use.
First-trimester oral exposure and birth defects
- Source A says
- MotherToBaby reports that its cited first-trimester studies did not show an overall increase in birth defects and describes minor eye or ear differences in a separate report that were not birth defects. (MotherToBaby: Phenylephrine Fact Sheet)
- Source B says
- Yau et al. found an association between first-trimester oral phenylephrine and endocardial cushion defect in four exposed cases; all four had multiple anomalies, and the authors said chance was possible because the exposed numbers were small. (Yau et al., Use of decongestants during pregnancy and the risk of birth defects, American Journal of Epidemiology (2013))
- Why they differ
- MotherToBaby reports an overall finding and a separate minor eye or ear result, while Yau et al. tested specific birth defects and reported a signal for one rare defect. Yau's signal rests on four exposed cases, and the authors say chance is possible because the number is small.
- Other sources
- The FDA injection label summarizes separate IV cesarean studies and explicitly does not provide first- or second-trimester data; it does not resolve the oral first-trimester findings. (FDA prescribing information: Phenylephrine Hydrochloride in 0.9% Sodium Chloride Injection)
- What the evidence shows overall
- The Yau result is a specific, low-count association and not proof of cause. The broad MotherToBaby finding and the specific study signal should both be presented with their limits.
Phenylephrine while breastfeeding
- Source A says
- LactMed and MotherToBaby report little or no direct human milk information; LactMed says oral exposure is unlikely to reach an infant but oral or IV use might reduce milk production. (LactMed (NIH): Phenylephrine, MotherToBaby: Phenylephrine Fact Sheet)
- Source B says
- NHS Specialist Pharmacy Service advises avoiding phenylephrine combination products if possible, especially with a newborn while breastfeeding is being established, while saying small transfer is expected and side effects are unlikely. (NHS Specialist Pharmacy Service: Using paracetamol during breastfeeding)
- Why they differ
- The sources emphasize different parts of an evidence gap. LactMed and MotherToBaby describe oral absorption and possible milk-supply effects, while NHS SPS gives a more cautious recommendation for combination products during early breastfeeding and describes expected transfer from drug properties. None reports established infant harm from maternal use.
- What the evidence shows overall
- Human milk levels and infant-effect information remain very limited. The possible concern is reduced milk production, not an established infant effect; the sources support describing the evidence as limited rather than presenting a confirmed infant risk.
- MotherToBaby says that, because there is little information about oral phenylephrine while breastfeeding, a nasal spray or another medication might be preferred. (MotherToBaby: Phenylephrine Fact Sheet)
General research, not specific to pregnancy.
Phenylephrine has oral, nasal, eye-drop, and IV uses, and regulator actions are route-specific. The FDA oral OTC action concerns effectiveness as a nasal decongestant, while the MHRA and EMA updates concern different product combinations and routes.
- FDA's 2023 advisory review and 2024 order concern oral phenylephrine used as an OTC nasal decongestant. The current FDA order table lists OTC000036 as "Proposed Order". FDA states that the action concerns effectiveness, not a pregnancy finding, and does not cover phenylephrine nasal sprays; IV injection is a separate product and setting. (FDA: Clarifies results of recent advisory committee meeting on oral phenylephrine, FDA: Oral phenylephrine OTC monograph order announcement, FDA OTC Monographs@FDA: Administrative Order Search)
- MHRA says not to use xylometazoline or oxymetazoline nasal products together or with other oral or nasal medicines for a blocked nose, including phenylephrine. (MHRA Safety Roundup: May 2026)
- EMA's 2026 review concerns phenylephrine/tropicamide ophthalmic products. It says their benefit-risk balance remains unchanged but product information should add a warning about necrotising enterocolitis in premature infants and list anaphylactic reaction and necrotising enterocolitis at unknown frequency. (EMA PRAC Minutes, 6 to 9 July 2026, EMA PSUSA: Phenylephrine/tropicamide)
- A separate EMA review of a specific cold-medicine combination containing phenylephrine hydrochloride had a regulatory outcome of Maintenance in June 2026. (EMA PSUSA: Ascorbic acid/caffeine/paracetamol/phenylephrine/terpine combination)
- MotherToBaby: Phenylephrine Fact SheetTeratology serviceSecondary
- Yau et al., Use of decongestants during pregnancy and the risk of birth defects, American Journal of Epidemiology (2013)US governmentPrimaryIndependent check
- FDA prescribing information: Phenylephrine Hydrochloride in 0.9% Sodium Chloride InjectionDrug company labelTertiaryIndependent check
- LactMed (NIH): PhenylephrineUS governmentSecondaryPage dated 2026-04-15
- NHS Specialist Pharmacy Service: Using paracetamol during breastfeedingUK governmentSecondaryPage dated 2024-10-11Independent check
- Mohta et al., Comparison of a Modified Regimen of Prophylactic Phenylephrine Boluses Versus Variable Rate Infusion During Elective Cesarean Delivery Under Spinal Anesthesia, Anesthesia & Analgesia Practice (2026)US governmentPrimaryIndependent check
- FDA: Clarifies results of recent advisory committee meeting on oral phenylephrineUS governmentSecondaryPage dated 2023-09-14
- FDA: Oral phenylephrine OTC monograph order announcementUS governmentSecondaryPage dated 2024-11-07
- FDA OTC Monographs@FDA: Administrative Order SearchDrug company labelSecondaryPage dated 2024-11-08
- MHRA Safety Roundup: May 2026UK governmentSecondaryPage dated 2026-05-28
- EMA PRAC Minutes, 6 to 9 July 2026EU agencySecondaryPage dated 2026-09-24European guidance
- EMA PSUSA: Phenylephrine/tropicamideEU agencySecondaryPage dated 2026-09-25European guidance
- EMA PSUSA: Ascorbic acid/caffeine/paracetamol/phenylephrine/terpine combinationEU agencySecondaryPage dated 2026-06-16European guidance
Last reviewed 2026-10-16
Independent check 2026-10-16
Not yet clinician-reviewed
Ask your provider about your situation.